About Apheris
At Apheris, we are building the future of how AI is applied in pharmaceutical R&D.
Our federated computing technology enables global pharma companies to collaborate securely on large AI models that accelerate drug discovery, without ever sharing their proprietary data. By powering multi-partner data networks across small molecules, antibodies, and protein folding, Apheris is redefining how science and AI intersect.
Apheris is a neutral technology and solutions provider. We do not conduct internal drug discovery research, and we do not develop proprietary drug assets. Instead, we support pharmaceutical computational drug discovery teams with production-grade applications, models, and infrastructure that help advance their own drug programs.
We currently host two flagship networks: the AI Structural Biology (AISB) Network, focused on protein co-folding and binding affinity prediction, and the ADMET Network, focused on small-molecule property prediction. In addition, we have just launched ApherisFold, an enterprise co-folding solution that enables pharma teams to deploy cutting-edge models such as OpenFold 3 and Boltz-2 directly within their own environments.
Our federated computing technology enables global pharma companies to collaborate securely on large AI models that accelerate drug discovery, without ever sharing their proprietary data. By powering multi-partner data networks across small molecules, antibodies, and protein folding, Apheris is redefining how science and AI intersect.
Apheris is a neutral technology and solutions provider. We do not conduct internal drug discovery research, and we do not develop proprietary drug assets. Instead, we support pharmaceutical computational drug discovery teams with production-grade applications, models, and infrastructure that help advance their own drug programs.
We currently host two flagship networks: the AI Structural Biology (AISB) Network, focused on protein co-folding and binding affinity prediction, and the ADMET Network, focused on small-molecule property prediction. In addition, we have just launched ApherisFold, an enterprise co-folding solution that enables pharma teams to deploy cutting-edge models such as OpenFold 3 and Boltz-2 directly within their own environments.